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ABSTRACT 
 
VENOUS THROMBOEMBOLISM: A CASE-CONTROL STUDY OF PATIENTS IN THE 
NEUROSCIENCE INTENSIVE CARE UNIT 
Rachel H. Wolfson, Mark D. Siegel. Section of Pulmonary and Critical Care, Department of Internal 
Medicine, Yale University, School of Medicine, New Haven, CT. 
 Venous Thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism 
(PE), is a significant source of morbidity and mortality in hospitalized patients.  However, despite ample 
research into VTE in hospitalized subpopulations, critically ill patients with primary neurological disorders 
have been insufficiently studied.  We hypothesized that there is a high incidence of VTE in the NICU 
despite a high thromboprophylaxis rate and that this population would carry a unique set of risk factors.  
Our goal was to identify those patients at higher risk for VTE who may then be served by more aggressive 
screening and thromboprophylaxis. 
 We performed a retrospective chart review and case-control study of patients admitted to the NICU 
of a major urban hospital for three or more days, between 2001 and 2005. The two groups were matched, 
2:1 (two controls per case), based on year of hospital discharge and presence of surgical intervention. 
 The incidence of VTE in the NICU was 9.5% (125 of 1,318 patients), despite an overall 
thromboprophylaxis rate of 97.6%. 55% of DVTs were in the upper and 45% in the lower extremity.  48 PE 
patients had PE.   Univariate analysis utilizing p<0.05 as a statistical threshold revealed 12 factors 
associated with VTE. These factors were entered into a multivariable analysis logistic regression, which 
yielded 5 factors that remained independently with VTE: higher rates were associated with use of a central-
venous catheter (OR:2.5, CI: 1.4 – 4.6, p=0.003), arteriovenous malformation (OR:4.9, CI: 1.2 – 20.1, 
p=0.026), prior VTE (OR:5.6, 1.4 – 22.4, p=0.014), and mechanical ventilation (OR:2.1, CI: 1.1 – 4.2, 
p=0.036).  VTE prophylaxis was protective (OR:0.8, CI: 0.0 – 0.9, p=0.043).  In conclusion, VTE remains 
common among NICU patients despite a high rate of prophylaxis.  Several factors appear to be associated 
with VTE in this population.  Future studies are needed to validate the association between these factors 
and VTE and to determine if more aggressive surveillance and prophylaxis can decrease the frequency and 
complications associated with VTE.  
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. 
INTRODUCTION 
History 
 
Venous thromboembolism (VTE) is a spectrum of disease encompassing deep 
venous thrombosis (DVT) and pulmonary embolism (PE). Peripheral vascular disease has 
been a long-known condition, first referenced in 1550 BC on the Ebers medical papyrus 
of Egypt. In 1644, Schenk first observed venous thrombosis when he described an 
occlusion in the inferior vena cava (1).   The concept that PEs most commonly originate 
from clots in lower extremity veins, was originally proposed by Rudolf Virchow and 
Armand Trousseau in 1846 (2).  Virchow’s Triad, first described in 1860, includes: 
venous stasis, vessel wall injury and hypercoagulable state, and is still considered the 
primary mechanism by which venous thrombosis occurs (3). 
Incidence  
The precise incidence of DVT is unknown because the condition is often 
misdiagnosed or is asymptomatic and may spontaneously resolve prior to reaching 
medical attention.  However, current estimates place the incidence of VTE in the general 
population around 117 per 100,000 people per year (48 DVT per 100,000, 69 PE per 
100,000) (4).  Similarly, another study places the incidence at 100 VTE per 100,000 
people, per year (5).  A study of the Olmstead County, Minnesota population showed an 
incidence of VTE of 1 per 1000 per year, consistent with prior studies (4). However, 
estimates of the number of people developing DVTs annually in the United States range 
from 250,000 (6, 7) to two million (8, 9). 
 Among hospitalized patients, the incidence of DVT is considerably higher and 
varies widely, from 13 to 80%, depending on the specific population studied (10 - 12).  
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Without prophylaxis, the incidence of DVT has been shown to be 10 to 20% among 
general medicine and 10 to 40% among general surgical patients, who were not receiving 
thromboprophylaxis (13), and 40 to 60% among patients specifically undergoing 
orthopedic surgery who did receive thromboprophylaxis (14). 
Among the ICU populations, the rates of DVT vary widely.  A study of the 
incidence of DVT in Medical Intensive Care Unit (MICU) patients demonstrated DVT in 
33%, despite an overall prophylaxis rate of 61% (15).  A study of Surgical Intensive Care 
Unit (SICU) patients demonstrated a DVT rate of 13% (10).  Finally, a study of critically 
ill patients undergoing mechanical ventilation for >7 days showed a DVT rate of 23.6%, 
despite a 100% of patients receiving prophylaxis consisting of either SCDs or 
subcutaneous heparin twice daily (11). 
Multiple neurological and neurosurgical populations have been studied thus far.  
One prospective trial of patients suffering acute spinal cord injury demonstrated a DVT 
rate of 26% without prophylaxis in the first two weeks (16).  The overall rate of DVT on 
a general neurosurgical service was 4% (17).  Among patients in neurorehabilitation, 
11% had DVT and the rate was higher among patients with brain tumor and intracerebral 
hemorrhage than with Traumatic Brain Injury (18). 
Morbidity and Mortality 
 
Estimates of hospitalizations related to DVTs place the rate at 270,000 
hospitalizations per year in the United States (9, 19).  Similarly, the Olmstead Co. study 
extrapolated the number of hospitalizations related to VTE in the U.S. at more than 
250,000, making it a topic of economic importance as well (4,6).  In fact, the 6-month 
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cost for inpatient treatment of DVT ranges from $3,906 - $17,168 per patient (20). An 
estimated 60,000 to 100,000 Americans die each year from PE (9, 21) and approximately 
10% of hospital deaths are attributable to PE (13).    
Most DVTs are clinically silent.  A study of major trauma patients found that only 
1.5% of patients with DVT had any symptoms suggestive of DVT, such as, pain, 
swelling, erythema, or palpable cord, despite a proximal DVT (a clot affecting the 
common or superficial femoral veins, or internal or external iliac veins) rate of over 57% 
(12).  One study of recent stroke patients showed death was the presenting manifestation 
in 50% of patients with PE, verifying that VTE may be clinically silent before 
culminating in death (22).  Although benefit has not been proven, these observations 
suggest that routine screening for DVT in asymptomatic patients may be valuable, 
particularly in high-risk populations, because waiting for symptoms to develop may cause 
clinicians to miss the majority of DVTs and place patients at risk for potentially life-
threatening PE.   
While most DVTs are clinically inapparent, they may become clinically 
important.  While the morbidity associated with clinically silent DVT is unknown, the 
morbidity associated with apparent DVT is considerable, and includes swelling, erythema 
and pain.  Post-thrombotic syndrome may ultimately result and is characterized by 
persistent swelling, pain, chronic ulcers and dermatitis. Among patients in the general 
population with a history of DVT, the rate of post-thrombotic syndrome ranges from 22% 
to 55% at 2 years, and over 29% at 8 years (23, 24).  In stroke patients who did not 
progress to PE, those whose DVTs were untreated had a rate of post-thrombotic 
syndrome approaching 90% (25).   
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In addition to the morbidity associated with DVTs, the thromboses may propagate 
and eventually embolize to the pulmonary circulation, resulting in PE.  Approximately 30 
to 40% of calf thromboses do propagate proximally (13, 26).  Furthermore, even those 
clinically silent DVTs in critical care patients pose a potential threat of embolization, as 
there is a significantly higher rate of PE in these patients than in those patients without 
DVT (19).  An article in the journal, Stroke, estimates that PE accounts for between 13 
and 25% of deaths within four weeks following acute stroke (27).  The International 
Cooperative Pulmonary Embolism Registry (ICOPER) was a registry of 2,454 patients 
with PE at 52 hospitals in 7 countries.  The study reported the overall mortality at 3 
months following PE was 17.4%. 45.1% of these deaths were attributable to PE (28).  
More effective prevention and treatment could decrease the number of patients with VTE 
and the morbidity and mortality associated with this condition.  
Risk Factors 
Multiple risk factors for VTE have been identified, most of which relate back to 
Virchow’s Triad of immobility, hypercoagulable state, and endothelial injury (29 - 32).  
(See Table 1 for previously identified risk factors of VTE).  General risk factors for VTE 
include: major surgery within the previous four weeks, pregnancy or the postpartum 
period, and immobilization (13, 30).  Age is another known risk factor for VTE: the 
Olmstead study demonstrated that for each 10-year increase in age, the incidence of VTE 
doubled (4, 6).  
Risk factors relating to medical history include malignancy, history of DVT, 
stroke leading to paresis or plegia, acute myocardial infarction (MI), congestive heart 
failure (CHF), nephrotic syndrome, ulcerative colitis (UC), and sepsis (13, 32).  Trauma 
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is another well-known risk factor for VTE due to associated endothelial injury (29).  
Specifically, multiple trauma, central nervous system (CNS)/spinal cord injury, burns, 
and lower extremity/long bone fractures have all been shown to be VTE risk factors (12). 
A number of vasculitides and hematologic disorders, many hereditary, result in a 
hypercoagulable state.  Examples include systemic lupus erythematosus (SLE) and the 
lupus anticoagulant, Behçet syndrome, homocystinuria, thrombocytosis and 
polycythemia rubra vera.  Inherited disorders of fibrinolysis and coagulopathies which 
predispose to VTE include Antithrombin III deficiency, Protein C and Protein S 
deficiency, Prothrombin 20210A mutation, Factor V Leiden, and dysfibrinogenemias and 
disorders of plasminogen activation (32). 
Certain drugs may contribute to or predispose to VTE.  Proven agents include oral 
contraceptives and estrogens.  In predisposed individuals, heparin may cause heparin-
induced thrombocytopenia, which can increase the risk of VTE (33).  Intravenous drug 
abuse predisposes to VTE as well (13, 26). 
Certain diagnoses among neurological/neurosurgical populations have been 
shown to be risk factors for DVT and are useful for identifying at-risk patients.  
Hemorrhagic stroke has been demonstrated to be an independent risk factor for DVT 
compared to patients with thrombotic stroke, though this study did not control for varying 
prophylaxis techniques (34).  Among neurorehabilitation patients, the rate of DVT was 
higher among patients with intracerebral hemorrhage (18).  Patients undergoing surgery 
for brain tumor removal were studied and the rate of DVT was found to be significantly 
higher among those undergoing craniotomy as opposed to other surgical approaches 
(9.5% vs. 3.7%) (17). Furthermore, specific risk factors for VTE among neurology 
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patients include gastrostomy tube, tracheostomy, and urethral catheter (35). Finally, a 
study of neurology patients found a 51-fold higher risk of DVT among patients with 
hemiparesis (36).  
Thromboprophylaxis 
 
Fortunately, there are effective options for prophylaxis against VTE.  Current 
practices rely primarily upon the use of low-dose anticoagulation and mechanical 
compression devices applied to the lower extremities (13).  When the risk of VTE is very 
high, prophylactic inferior vena cava (IVC) filter placement may be used to prevent clots 
from reaching the pulmonary circulation when they embolize (13).   
Mechanical methods of thromboprophylaxis are based upon the concept of 
reducing venous stasis and inducing anti-thrombotic, pro-fibrinolytic, vasodilatory 
biochemical alterations.  The minor endothelial shear stress induced by the Sequential 
Compression Devices causes the release of nitric oxide, tissue plasminogen activator and 
prostacyclin, and decreases levels of plasminogen activator inhibitor, decreasing the risk 
of clot formation (37).  A meta-analysis appearing in Chest, the journal of the American 
College of Chest Physicians, found that while no mechanical method of 
thromboprophylaxis has been shown to reduce the rate of PE or death, they are effective 
in reducing rates of DVT and may be a good alternative in patients for whom 
anticoagulation is contraindicated (13).  Another meta-analysis of original studies 
between 1966 and 1996 demonstrated a 62% reduction in the rate of DVT with SCD use 
compared with placebo (38). A study of serial compression devices (SCDs) in 1998 
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demonstrated a more than 40-fold risk reduction when SCDs were added to 
anticoagulation with 5000 units of heparin twice daily in thrombotic stroke patients (36).   
Anticoagulation has been a known method of preventing and treating VTE since 
the 1960s.  Current anticoagulation practices vary, but most commonly involve the use of 
unfractionated heparin (UFH), usually 5000 units subcutaneously twice or three times 
daily, or low molecular weight heparin (LMWH). The first evidence that heparin reduces 
mortality in patients with PE was presented in Lancet in 1960 (39).  Both LMWH and 
UFH have been proven effective in prophylaxis against VTE (40).  (See Tables 2 - 4 for a 
summary of thromboprophylaxis available and the studies investigating the efficacy of 
various methods of thromboprophylaxis.)  Both LMWH and UFH have been endorsed by 
the American Stroke Association, the American Academy of Neurology, and the 
American Heart Association as effective and safe when used subcutaneously for VTE 
prophylaxis, with a low rate of hemorrhage after ischemic stroke (41).  The American 
College of Chest Physicians recommends the use of LMWH or low-dose UFH, as well as 
SCDs, for use as thromboprophylaxis in most medical and surgical populations (13, 42). 
A 2004 study demonstrated the efficacy of therapeutic anticoagulation and 
heparin prophylaxis during stroke rehabilitation in prevention of VTE, as well as the 
inferior efficacy of antiplatelet agents in this population (35). A meta-analysis of VTE 
prophylaxis of surgical patients demonstrated that LMWH was at least as effective as 
UFH in reducing the incidence of VTE (40).  However, a very recent study demonstrated 
the superiority of LMWH over unfractionated heparin for DVT prophylaxis after 
ischemic stroke, based on its once daily administration schedule, and its increased 
effectiveness at preventing VTE (43).   
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The Cochrane review demonstrated a three-fold increase in bleeding risk when 
stroke patients receive full anticoagulation after stroke (44).  In contrast, a 2002 study 
demonstrated no increased bleeding in patients with severe head injury receiving early 
unfractionated heparin as thromboprophylaxis (45).  More generally, most studies have 
shown minimal risk of hemorrhage in the average hospital patient receiving 
thromboprophylaxis with low dose heparin along with a favorable risk:benefit ratio to its 
use (13).  While individual methods of prophylaxis are effective, a 1998 study 
demonstrated the improved efficacy, in a neurosurgery population, of using Lovenox and 
SCDs combined, when compared to SCDs alone (5% DVT rate vs. 13% DVT rate, 
respectively). The study also showed no increased bleeding risk in this population (46).  
The finding of improved efficacy with two forms of thromboprophylaxis was verified for 
SCDs and UFH as well (36).     
Despite the evidence demonstrating the efficacy of thromboprophylaxis, and 
current guidelines recommending its use, a study in the 1990s estimated that only one-
third of hospitalized patients with multiple risk factors for VTE received prophylaxis 
(47).  More recently, the 2008 multinational cross-sectional ENDORSE study 
investigated the percentage of hospitalized patients who would qualify for VTE 
prophylaxis based on current guidelines. The study found that nearly half of all 
hospitalized patients meet criteria for thromboprophylaxis, yet only half of those patients 
received prophylaxis (48).  This lack of consistent thromboprophylaxis is apparently 
resulting in a large number of preventable VTE.  A 2001 study showed that over 17% of 
VTE in inpatients was potentially preventable if proper prophylaxis had been 
implemented. (49). Therefore, despite clear evidence for the safety and efficacy of 
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thromboprophylaxis, and the detrimental effects of withholding prophylaxis, the 
intervention remains underutilized.   
Upper Extremity DVT  
Current studies indicate that 1 to 4% of DVTs involve the upper extremities 
(UEDVT), primarily the subclavian, axillary, brachial or internal jugular veins.  UEDVTs 
can be divided into primary (unprovoked) and secondary (e.g., in the setting of central 
venous catheter, cancer or pacemaker), the latter making up 75 to 80% of cases (42, 31).  
Primary UEDVT is quite rare and is usually either idiopathic, or due to effort or exertion 
leading to microtrauma, called Paget-Schroetter Syndrome (50).  UEDVTs have unique 
risk factors and include use of pacemakers and central venous catheters.  Furthermore, 
patients with UEDVT are less often Caucasian and more likely to be younger, leaner, and 
smokers compared with those with LEDVT (51).  
The American College of Chest Physicians (ACCP), in Chest 2008, determined 
that there have been no randomized-controlled trials investigating the efficacy of 
unfractionated heparin or low-molecular weight heparin for the treatment of UEDVT.  
However, there have been sufficient smaller studies to support the use of both as 
prophylaxis against UEDVT (42).  Moreover, like previous DVT prophylaxis studies, a 
2004 study showed that only 20% of patients with UEDVTs, without any 
contraindication, actually received prophylaxis (51). 
Chest also provided a meta-analysis of UEDVT studies investigating the outcome 
and side effects of interventions.  Fewer patients with UEDVT present with overt PE, 
compared to those with lower-extremity DVT.  However, their three-month outcome in 
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terms of recurrent DVT or PE, major or fatal bleeding, or fatal PE, is similar (52).  While 
rare, UEDVTs do embolize, leading to potentially fatal PEs (52).  However, the estimates 
of PE among patients with UEDVT have varied widely.   One study found that up to one-
third of patients with UEDVT may suffer from PE (53), while another study found a 
vastly lower incidence of PE in the range of 0.5% to 4% (54).  This discrepancy 
highlights the great variation in findings related to UEDVT. One likely explanation may 
be variations in screening practices.  As with any condition, when it is screened for, 
UEDVT is more likely to be discovered.   In either case, the presence of proximal 
UEDVTs is clinically significant and treatment is recommended (42).   
It should be noted that location of proximal UEDVT does not appear to influence 
risk of embolism. One study found no significant difference in risk of embolism between 
internal jugular vs. subclavian and/or axillary vein DVTs (54).  However, there should be 
a suspicion of lower extremity DVT in patients with UEDVT, because the two are often 
comorbid (55). 
Finally, while superficial vein thrombosis (SVT), also known as superficial 
thrombophlebitis, is generally considered benign, studies have shown rates of 
thromboembolic complications ranging from 5-15% (56).  Most studies, however, have 
focused on lower extremity SVT; upper extremity SVT remains understudied.  However, 
the ACCP recommends treatment of SVT with prophylactic doses of LMWH after 
ultrasound verification of the absence of concurrent DVT (42).  
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In summary, while there is an apparent lower incidence of clinically overt PE in 
patients with UEDVT, they do embolize and, as such, should be considered clinically 
significant.    
Previously Studied Populations 
Previous studies of VTE have examined a variety of inpatient populations, 
including neurosurgical, spinal cord injury, and Medical Intensive Care Unit (MICU) 
populations (10 - 12, 15 - 18, 34, 35, 57,).  Detailed recommendations have been made 
regarding subpopulations of both medical and surgical patients (e.g., laparoscopic 
surgery, knee and hip arthroplasty, gynecologic surgery, urologic surgery, trauma, burns, 
and cancer patients).  (See Table 5 for data on DVT prevalence in previously studied 
populations).   
However, despite the extensive research in this area, to date 
Neurological/Neurosurgical ICU (NICU) patients have never been studied specifically. 
There are several reasons to suspect that NICU patients are at high risk for VTE.   First, 
ICU patients in general tend to have numerous risk factors for VTE: they are often 
immobile, mechanically ventilated, sedated, septic, with central venous catheters, or 
suffering from respiratory or cardiovascular failure.  Second, certain patient-types 
common in the NICU, such as neurosurgical patients and acute spinal cord injury patients 
have been studied individually and shown to be subject to high rates of VTE (13, 16 - 18, 
29, 57).   
Further, this population includes patients suffering from unique medical 
conditions, including brain tumor, epilepsy, intracerebral, subarachnoid and subdural 
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hemorrhage, spinal cord injury, hydrocephalus and cerebral aneurysms. This population 
also presents distinctive challenges with regard to anticoagulation.  For example, patients 
in the NICU due to intracranial hemorrhages (intracerebral, subdural, epidural or 
subarachnoid) pose a particular problem in determining appropriate prophylaxis.  
Clinicians are often concerned about providing any anticoagulation in this subpopulation, 
even though only full anticoagulation increases the risk of worsening hemorrhage or 
rebleed after the initial insult (44).  A meta-analysis performed in Stroke, showed a 
significantly increased risk of hemorrhage after ischemic stroke when higher, therapeutic 
doses of either UFH or LMWH were used, highlighting the unique VTE treatment 
challenges faced by this population (41). Oftentimes these patients may only be 
mechanically prophylaxed, which may be less effective than anticoagulants for 
thromboprophylaxis.  Therefore, these patients, though theoretically at significant risk for 
VTE, may, as a result of their neurological condition, not receive effective prophylaxis.   
Moreover, the development of DVT in the NICU creates problematic treatment 
choices because, for many patients, full anticoagulation could increase the risk of central 
nervous system hemorrhage.  Therefore, the ability to identify NICU patients at highest 
risk for VTE could allow them to be targeted for closer screening and potentially more 
aggressive thromboprophylaxis.  This could decrease risk for VTE as well as the potential 
consequences of treatment, extended hospital stay, and consumption of additional 
hospital resources.  
HYPOTHESIS 
VTE in the NICU is common, despite near-universal use of prophylaxis, and 
specific factors can be identified to help identify those patients at higher risk for VTE.   
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STATEMENT OF PURPOSE 
The goal of this study was to examine the NICU population and answer the 
following questions: 
1. What is the incidence of VTE in NICU patients? 
2. What risk factors predispose NICU patients to develop VTE? 
3. What is the clinical outcome of NICU patients with VTE?  That is, what are their 
rates of mortality, pulmonary embolism, associated complications and lengths of 
NICU and total hospital stay? 
In investigating the incidence of VTE within the NICU population, it may be determined 
whether this population is generally well-served by continuing thromboprophylaxis, 
despite risk of hemorrhage.  Further, if a particular subgroup of the NICU population 
could be identified as at increased risk of developing VTE, then this subpopulation could 
be targeted for more aggressive surveillance and prophylaxis, for example, with higher 
dose anticoagulation or prophylactic insertion of an IVC filter.  
METHODS 
With approval from the Human Investigation Committee of Yale University, an 
Excel file was obtained from Janis Bozzo, MSN, RN, Clinical Coordinator, Decision 
Support, Yale-New Haven Health System, and an Assistant Clinical Professor, Yale 
School of Nursing, New Haven, CT.  The file contained a list of all patients who were 
coded as having stayed in the NICU for three days or longer, discharged between January 
1, 2001, and December 31, 2005, under the care of the Neurology or Neurosurgical 
services.  The Excel file also included name, age, gender, race, principal operation 
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performed (if any), principal diagnosis, dates of hospital admission and discharge, and 
whether the patient was coded as having a DVT. The total number of patients on the 
Excel file provided by Ms. Bozzo was 1,318.   This approach was the most complete way 
to capture the entire population of NICU patients between 2001 and 2005.  All 
subsequent data collection was performed by Rachel Wolfson, medical student.  
For each patient listed in the Excel file, an independent review was conducted to 
verify acute DVT diagnosis and investigate those patients with documented PE as well.  
This review was conducted using Sunrise Clinical Manager, the Yale-New Haven 
Hospital electronic medical record, and all diagnostic imaging related to DVT/PE.  The 
imaging modalities included Doppler ultrasounds (DUS) of upper and lower extremities, 
computerized tomographic angiography (CTA) - P.E. Protocol, ventilation/perfusion 
(V/Q) scans, and angiography/venography.  If a DUS showed a nonocclusive or occlusive 
thrombus in any of the deep veins of the lower extremities or of the brachial, basilic, 
axillary, internal jugular or subclavian veins of the upper extremities, this was 
documented as a positive result.  Additionally, a positive CTA, or a high 
probability/intermediate probability V/Q scan, were documented as a positive result.  
Intermediate V/Q scans were considered positive for VTE because these patients were 
treated clinically as though they had a PE. According to the Excel file, 77 patients had 
documented DVT, whereas after review, 104 patients had documented DVT.     
Because this is a case-control study, those patients with positive results (acute 
VTE) during NICU stay or within 3 days after NICU discharge were considered our 
cases.  Patients with VTE during their hospital stay but prior to NICU admission were not 
considered cases.  There were 125 cases (104 patients with DVT and 21 with isolated PE) 
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matched 2 controls per case.  The groups were matched on year of discharge from the 
hospital to control for any temporal changes regarding DVT prophylaxis and screening.  
The groups were also matched on whether a surgery of any kind was performed during 
the hospitalization*.  
The matching was conducted by the following process: for each case group (e.g., 
2004, surgery, VTE), the eligible controls (2004, surgery, no VTE) were assigned a 
number.  Then, using a number randomizer from the website: 
http://www.randomizer.org/form.htm, the requisite number of random numbers was 
generated.  That is, if ten controls were needed, ten random numbers were generated and 
the eligible controls corresponding to those random numbers were then chosen as 
controls.  This was done in order to prevent selection bias.  
Data for all cases and controls were gathered from two sources: Sunrise Clinical 
Manager/CCSS from hospital computers, and paper charts pulled with the assistance of 
the YNHH medical records department.  Data was collected first on a Microsoft Word 
form (see Figure 1).  All information was saved on both a thumb-drive and hard drive of 
a personal computer, both of which were password protected and designated to be 
destroyed following completion of the study.  Dr. Mark D. Siegel (MDS) and Rachel H. 
Wolfson (RHW) were the only two investigators with access to the files.  Throughout the 
data collection process, the data was periodically entered, and rechecked, into a Microsoft 
Access Database, created by RHW.  The database was then used to analyze our results.1   
                                                 
1
 Appendix 1 contains detailed descriptions of how each data-point was defined and the 
specific chart locations where that data-point was gathered.  
*During data collection, 13 cases were discovered with surgery after VTE diagnosis.  
However the results of the study are largely the same with and without inclusion of this 
population.  
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ANALYSIS 
Analysis was performed by RHW with assistance from MDS and James Dziura, 
PhD., biostatistician.  Data from the Microsoft Access database were imported into Excel 
files and into Statistical Package for the Social Sciences (SPSS) version 17.0 for analysis.   
First, for the cases, an analysis of VTEs was undertaken, including number, 
location, and outcome, specifically, length of stay, mortality, and complications.  
Furthermore, the NICU population as a whole (cases and controls) was described using 
the following variables: 
1.  General descriptive data, including: incidence of underlying pre-existing 
medical problems, age, height, weight, BMI, days admitted to the hospital and 
NICU, and Glascow Coma Score (GCS).  Using kurtosis as a measure of 
normality of distribution, those variables with kurtosis < +/- 1.00 were 
described with mean +/- SD and those variables with kurtosis > +/- 1.00 were 
described using median with quartiles.  Chi-squared was used to describe race, 
smoking status and alcohol consumption.   
2.   Primary diagnosis- number and percentage of each diagnosis was calculated. 
3.   Use of central venous catheters or PICC lines– number and percentage of each 
type of central venous catheter was calculated, 
4.  Use of ultrasounds and Computerized Tomography Pulmonary Angiograms.     
To evaluate the relationship between number of scans and yield over time 
Spearman Correlation tests were used.  Using Epi Info Version 3.5.1 (CDC), 
chi square for trend was calculated to measure case rate according to year.   
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5. Administration of prophylaxis, and type – number and percentage of 
thromboprophylaxis techniques were described  
6. Outcomes – to compare lengths of NICU and hospital stays, Mann-Whitney U 
tests were performed. Number of deaths, and complications were also given. 
Second, to measure differences between cases and controls, and identify potential 
risk factors for VTE, binary logistic regression was used.  Initially, univariate screening 
with binary logistic regression, including calculation of p-values and odds ratios with 
95% confidence intervals, was performed on 50 potential risk factors.  A multivariable 
logistic regression model was created in order to identify variable(s) showing an 
independent association with VTE.  To be eligible for entry into the multivariable 
analysis, factors had to meet the following criteria: 1) p<0.05 and clinically useful on 
univariate analysis, To be considered “clinically useful,” a variable found to be 
significant on univariate analysis had to be present upon admission to the NICU or 
represent an intervention occurring during the NICU stay but before detection of VTE.  
Goodness-of-fit was assessed using the Hosmer – Lemeshow test.  All statistical analyses 
were performed using two-tailed testing with a p-value <0.05 taken as a threshold to 
indicate statistical significance.  
RESULTS 
General Descriptive Results 
1,318 patients were admitted to the NICU for three or more days on the neurology 
or neurosurgical services at Yale New-Haven Hospital between January 1, 2001 and 
December 31, 2005.  Of the 1,318, 125 cases (9.5%) had DVT, PE, or both. 
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Characteristics of the Study Population 
Characteristics of the study population are summarized in Table 6, below.  
Table 6: Characteristics of the Study Population 
Characteristic 
Number of Cases 
(N=125) 
Number of Controls 
(N=250) 
Race 
Caucasian, % 97, (77.6%) 197, (78.8%) 
African-American, % 14, (11.2%) 31, (12.4%) 
Hispanic, % 13, (10.4%) 17, (6.8%) 
Asian, % 1, (0.8%) 3, (1.2%) 
Other Race, % 0 2, (0.8%) 
GCS (median, IQR) 11 (6-14) 13 (6-15) 
General Characteristics 
Height (mean +/- SD), cm 171.6 (+/- 10.9) cm 168.3 (+/-10.8) cm 
Weight (mean +/- SD), kg 85.0 (+/-24.4) kg 77.1 (+/-19.6) kg 
BMI (mean +/- SD), 
kg/(m^2) 
28.7 (+/-7.6) kg/(m^2) 27.2 (+/-6.4) kg/(m^2) 
Age (mean +/- SD) years 55.2 (+/-16.9) years 54.2 (+/-18.5) years 
Gender (N female), % 56 (44.8%) 141 (56.4%) 
Never Smoker, % 47 (37.6%) 129 (51.6%) 
Former Smoker, % 18 (14.4%) 33 (13.2%) 
Current Smoker, % 31 (24.8%) 72 (28.8%) 
No EtOH, % 49 (39.2%) 130 (52.0%) 
 19 
  
. 
Social/Occasional EtOH, % 34 (27.2%) 62 (24.8%) 
Abusing/Excessive EtOH, 
% 
14 (11.2%) 40 (16.0%) 
Diagnoses 
Subarachnoid hemorrhage 48 (38.4%) 77 (30.8%) 
Plegia/Paresis 43 (34.4%) 48 (19.2%) 
Cerebral aneurysm 31 (24.8%) 65 (26.0%) 
Intracerebral hemorrhage 30 (24.0%) 31 (12.4%) 
Brain Tumor 17 (13.6) 40 (16.0%) 
Other* 13 (10.4%) 39 (15.6%) 
Subdural hemorrhage 13 (10.4%) 28 (11.2%) 
Thrombotic stroke 8 (6.4%) 13 (5.2%) 
Spinal Cord Injury 3 (2.4%) 15 (6.0%) 
Ateriovenous Malformation 
(AVM) 
9 (7.2%) 7 (2.8%) 
C-spine fracture 4 (3.2%) 9 (3.6%) 
Traumatic Brain Injury 5 (4.0%) 4 (1.6%) 
Hydrocephalus 3 (2.4%) 9 (3.6%) 
Skull Fracture 4 (3.2%) 6 (2.4%) 
Epilepsy 4 (3.2%) 6 (2.4%) 
Medical History 
Atrial Fibrillation, % 12 (9.6%) 21 (8.4%) 
Prosthetic Valves, % 1 (0.8%) 4 (1.6%) 
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Cardiomyopathy, % 4 (3.2%) 1 (0.4%) 
History of MI, % 6 (4.8%) 2 (0.8%) 
Hypertension, % 38 (30.4%) 97 (38.8%) 
Leg Fracture, % 1 (0.8%) 8 (3.2%) 
Prior VTE, % 9 (7.2%) 4 (1.6%) 
Malignancy, % 15 (12.0%) 39 (15.6%) 
Metastases, % 5 (4.0%) 14 (5.6%) 
Home Medications 
Aspirin, % 10 (8.0%) 32 (12.8%) 
Coumadin, % 10 (8.0%) 11 (4.4%) 
Plavix, % 4 (3.2%) 4 (1.6%) 
NICU Interventions 
Mechanical Ventilation, % 102 (81.6%) 144 (57.6%) 
Sedation, % 56 (44.8%) 74 (29.6%) 
Paralytics, % 8 (6.4%) 12 (4.8%) 
Bed Rest, % 120 (96.0%) 236 (94.4%) 
Tracheotomy, % 16 (12.8%) 123 (9.2%) 
Central Venous Catheter, % 91 (77.6%) 124 (49.6%) 
 
Surgery 
469 total surgeries were performed on 320 total cases and controls (84.7%), of 
which 46.5% involved craniotomies and 4.7% involved burr holes.  71.0% used 
intraoperative VTE prophylaxis, usually in the form of SCDs.  Failure to use 
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intraoperative prophylaxis was not significantly associated with VTE (OR: 0.8, CI: 0.5 – 
1.1, p=0.169).  Table 7 summarizes the surgeries performed on the population (cases and 
controls). 
 
Table 7: Frequency of Surgery Types 
 
Type of Surgery Frequency 
Percent of 
Surgeries 
Other* 180 38.4% 
Vascular Surgery 110 23.5% 
Evacuation of blood 70 14.9% 
Tumor removal 52 11.1% 
Shunt insertion 35 7.5% 
Spinal surgery 19 4.1% 
Total 469 100% 
*Other surgery includes tracheotomy, cranial reconstruction, wound debridement, 
ventriculostomy, pacemaker insertion, open reduction internal fixation of long bones, 
abscess drainage, and grid strip placement and removal 
Incidence 
Of the 125 VTE cases discovered, 104 were DVTs: 67 upper (64.4%), 54 lower 
(51.9%), 17 both (16.3%).  Of the 104 DVT cases, 77 were DVT only (74.0%), and 27 
were both DVT and PE (26.0%).  There were 48 PEs (38.4% of cases) of which 21 were 
PE only (16.8% of cases).   Table 8 contains a summary of VTE prevalence. 
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Of the cases of PE, 11 of the 48 (22.9%) had demonstrated lower extremity DVTs 
either prior to, or at the time of PE discovery.2  Further, 9 of the PEs (18.8%) had 
UEDVTs, 8 (16.7%) had both upper and lower extremity DVTs, and 20 (41.7%) had no 
identified DVT, despite a verified PE. 
Table 8: Summary of VTE Occurrence 
Type of VTE Number of Cases 
VTE 125 
DVT Total 104 
DVT only 77 
PE only 21 
DVT and PE 27 
UEDVT only  50 
LEDVT only 37 
UEDVT and LEDVT 17 
 
Figure 2 describes how soon after NICU admission, patients were diagnosed with 
VTE. The median length was 8 days (IQR: 4 – 15 days).  
                                                 
2
 Occasionally DVT was discovered several days after initial PE and this was counted as a potential source 
of the PE if no other DVT was discovered at the time of PE diagnosis.   
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Cephalic Thromboses 
42 patients had cephalic clots.  Cephalic clots qualify as superficial 
thrombophlebitis, also known as superficial vein thrombosis, and therefore those patients 
with cephalic clots only, were not considered cases or included for further analysis.  19 
patients with cephalic clots never developed VTE.  However, 16 patients who were 
positive for cephalic clot only, initially, were subsequently shown to have true UEDVT.  
7 patients with cephalic clot initially, were subsequently shown to have PE.  This 
suggests that cephalic thromboses may, in fact, propagate and embolize to become VTE.   
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Use of Imaging 
44 of the 48 PEs were diagnosed by CTA, and four by V/Q scan.  There were 27 
imaging episodes for PE that were negative, resulting in a 63.2% yield (48 positive 
scans/76 total scans). There were 625 total lower extremity Doppler ultrasounds (DUS) 
with 122 positive results, a yield of 19.5% (122/625).3  There were 207 total upper 
extremity DUS, with 169 positive results, a yield of 81.6%.   
To evaluate screening practices, the number of ultrasounds was further 
investigated. The median number of ultrasounds per patient was 1 scan (IQR: 0-2).  Cases 
received a median of 2 (IQR: 1-3) scans per patient and controls received 1 (IQR: 0-2) 
scan per patient.   The median number of ultrasounds per patient per week for the entire 
population was 0.44 scans (IQR 0.00 – 0.78).  Cases received a median of 0.45 (IQR: 
0.22 – 0.71) scans/patient/week while controls received 0.41 (IQR: 0.00 – 0.78) 
scans/pt/week (p=0.063).  That is, cases received more ultrasounds per patient and per 
patient per week, compared to controls.  142 of the 250 controls (56.3%) received at least 
one scan during their NICU stay, which means nearly 40% of controls were not evaluated 
for VTE.  
Hospital Year 
In the entire NICU patient population (N=1,318), the percentage of patients 
diagnosed with VTE was highest in 2004 (14.1%) and lowest in 2001 (5.7%).   The 
percent of NICU patients diagnosed with VTE increased over the years of the study (Chi-
Square for trend, p=0.009) (Table 9).  
                                                 
3
 This includes repeat ultrasounds after the initial DVT was discovered. 
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In the study population (restricted to those entered into the case-control study, 
N=375), the number of ultrasounds increased annually from 2001 to 2005 (Spearman’s 
rho= 0.900, p=0.037).   From 2001 to 2005, there was a trend towards a lower rate of 
DVT diagnosed on ultrasounds performed (Chi-Square for trend, p=0.06) (Table 10).  
The rate of ultrasounds positive for DVT was negatively correlated with the number 
performed each year (Spearman’s rho=-0.900, p=0.037), suggesting the possibility that 
more ultrasounds were being done for routine screening, rather than due to the presence 
of clinical symptoms.  At the same time, in any given year, the number of ultrasounds 
correlated with the number of DVTs discovered (Spearman’s rho=1.000, p=0.01), 
suggesting that the apparent prevalence in any given year might be related, at least 
partially, to the number of scans performed. 
  Table 9: Incidence of VTE Cases per Year 
 
Year 
Total Number of 
Patients Per Year 
(N=1,318) 
Number of VTE 
Cases 
(N=125) 
Percentage of Admissions 
2001 229 13 5.7% 
2002 272 19 7.0% 
2003 245 25 10.2% 
2004 271 38 14.1% 
2005 301 30 10.0% 
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Table 10: Ultrasounds and Yield per Year 
Year 
Number of Cases 
per Year 
Number of Ultrasounds 
on the Study Population 
(N=375) 
Yield (Number of 
Cases per 
year/Number of 
Ultrasounds per 
Year) 
2001 13 66 19.7% 
2002 19 97 19.6% 
2003 25 158 15.8% 
2004 38 280 13.6% 
2005 30 229 13.1% 
Thromboprophylaxis 
97.6% of patients received some kind of VTE prophylaxis.  Only two controls and 
seven cases did not receive prophylaxis. That is, 99.2% of controls and 94.4% of cases 
received some kind of VTE prophylaxis.  Cases were less likely to receive 
thromboprophylaxis compared to controls.  Thromboprophylaxis was significantly 
protective against VTE development (OR: 0.2, CI: 0.0 – 0.8. p=0.025). Use of an 
increasing number of thromboprophylaxis modalities (heparin bid, heparin tid, SCDs, or 
Lovenox) employed during NICU stay, was protective against VTE (OR: 0.6, CI: 0.4 – 
0.9, p=0.025).  67.1% of patients received two forms of thromboprophylaxis, while 
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30.2% received one.  Table 11 summarizes the percentage of patients receiving 
prophylaxis. 
Table 11: Thromboprophylaxis Received  
Type of 
Thromboprophylaxis 
Received 
Number of Cases 
(N=125) 
Number of 
Controls  
(N=250) 
P-value 
Heparin bid, % 77 (61.6%) 173 (69.2%) 0.395 
Heparin tid, % 3 (2.4%) 13 (5.2%) 0.216 
Lovenox, % 3 (2.4%) 3 (1.2%) 0.386 
Mechanical Compression 
Devices, % 
111 (88.8%) 235 (94.0%) 0.621 
Treatment of VTE 
 
Treatment for DVT was generally insertion of an IVC filter, or IV unfractionated 
heparin, or both.  Of the 125 cases, 67 received an IVC filter (53.6%). Further, 38 cases 
received IV unfractionated heparin (30.4%) for VTE treatment, 16 (12.8%) received both 
IV UFH and IVC filter.    
Morbidity and Mortality 
 
There was a trend towards increased mortality among patients with VTE.  Only 
one death was related to PE, perhaps due to the paucity of autopsies and the difficulty 
determining cause of death from the charts.  Patients with VTE spent more time in both 
the hospital and NICU.  
There were two cases of heparin-induced thrombocytopenia (HIT), both in 
patients VTE receiving unfractionated IV heparin for VTE treatment.  Neither of the 
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patients who experienced HIT died as a result. None of the patients given anticoagulation 
for VTE had a significant bleed as a result.  The median NICU stay of cases after VTE 
diagnosis was 8 (IQR: 2-16) days.   The length of NICU stay after VTE diagnosis in 
cases compared to total length of NICU stay of controls, was not significantly different 
(OR: 0.997, CI: 0.987 – 1.007, p=0.568).  The median hospital stay of cases after VTE 
diagnosis was 17 (IQR: 9-28.75) days.  The length of hospital stay after VTE diagnosis in 
cases compared to total length of hospital stay of controls, was not significantly different 
(OR: 1.008, CI: 0.999 – 1.017, p=0.087).  This indicates that the increased length of stay 
may not be due to the presence of VTE.  Table 12 summarizes the morbidity and 
mortality associated with VTE. 
Table 12: Morbidity and Mortality Associated with VTE 
Outcome Cases (N=125) 
Controls 
(N=250) 
OR (95% CI) P-value 
Length of NICU 
Stay (median, IQR), 
days 
18.5 (10-30) days 6 (4-11) days 
1.024 (1.01 – 
1.04) 
0.005 
Length of Hospital 
Stay (median, IQR), 
days 
31 (16.5 – 46) 
days 
13 (8-19) days 
1.02 (1.01 – 
1.03) 
<0.001 
Death, % 19 (15.1%) 22 (8.7%) 
OR: 1.9 (1.0 – 
3.6) 
0.060 
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NICU Population and Potential Risk Factors: Univariate Analysis 
Tables 13 – 18 describe the demographic and clinical features of the study 
population (125 cases, 250 controls) and their association with VTE. 
Table 13: Race of the NICU Population and Association with VTE 
Race OR (95% CI) P-value 
Caucasian, % 0.9 (0.6 – 1.6) 0.790 
African-American, % 0.9 (0.5 – 1.7) 0.736 
Hispanic, % 1.6 (0.7 – 3.4) 0.229 
Asian, % 0.66 (0.07 – 6.45) 0.724 
Other Race, % 0.000 (0.000 - *) 0.999 
General Characteristics 
Table 14 summarizes the general characteristics of the study population. Cases 
were less likely to be female (OR: 0.6, CI: 0.4 – 1.0, p=0.034). Cases were also taller 
and heavier than controls.  Specifically, height (OR: 1.03 per cm, CI: 1.01 – 1.05, 
p=0.010) and weight (OR: 1.0 per kg, CI: 1.01 – 1.03, p=0.002) were both significantly 
associated with VTE, although BMI was not.  Of note, BMI could not be calculated for 
all patients because height, weight, or both were unknown, so the missing data may have 
contributed to lower statistical power.  Plegia on admission to the NICU was significantly 
associated with VTE (OR: 2.2, CI: 1.4 – 3.6, p=0.001), but GCS and age were not.  
Table 14: NICU characteristics 
Characteristic/Variable Odds Ratio (95% CI) P-value 
GCS  0.96 (0.92– 1.01) 0.119 
Height 1.03 per cm(1.01 – 1.05) 0.010 
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Characteristic/Variable Odds Ratio (95% CI) P-value 
Weight 1.0 per kg (1.01– 1.03) 0.002 
BMI 
1.033 per kg/(m^2) (0.999 
– 1.067) 
0.055 
Age  1.0 per year (0.99 – 1.02) 0.613 
Gender (female) 0.6 (0.4 – 1.0) 0.034 
Never Smoker 0.8 (0.5 – 1.3) 0.308 
Former Smoker 1.4 (0.7 – 2.6) 0.290 
Current Smoker 1.1 (0.6 – 1.8) 0.786 
No EtOH 0.8 (0.5 – 1.3) 0.360 
Social/Occasional EtOH 1.5 (0.9 – 2.5) 0.131 
Abusing/Excessive EtOH 0.8 (0.4 – 1.6) 0.531 
Diagnoses 
 
The most common diagnosis in the NICU study population was subarachnoid 
hemorrhage (33.3%).  See Table 15 for a summary of the most common NICU diagnoses 
and their prevalence.  
A diagnosis of intracerebral hemorrhage or arteriovenous malformation (AVM) 
was associated with VTE on univariate analysis.  No other neurological or neurosurgical 
diagnosis was associated with VTE, as shown in Table 15. 
Table 15:  Neurological Diagnoses and Association with VTE 
Diagnosis 
Odds Ratio 
(95% CI) 
P-value 
Subarachnoid hemorrhage 0.1 (0.9 – 2.2) 0.142 
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Diagnosis 
Odds Ratio 
(95% CI) 
P-value 
Plegia/Paresis 2.2 (1.4 – 3.6) 0.001 
Cerebral aneurysm 0.9 (0.6 – 1.6) 0.835 
Intracerebral hemorrhage 2.3 (1.3 – 3.9) 0.004 
Brain Tumor 0.8 (0.5 - 1.5) 0.562 
Other* 0.6 (0.3 – 1.2) 0.181 
Subdural hemorrhage 0.9 (0.5 – 1.9) 0.835 
Thrombotic stroke 1.3 (0.5 – 3.1) 0.621 
Spinal Cord Injury 0.4 (0.1 - 1.4) 0.141 
Ateriovenous Malformation 
(AVM) 
4.8 (1.5 – 16.0) 0.010 
C-spine fracture 0.9 (0.3 – 3.0) 0.853 
Traumatic Brain Injury 1.5 (0.5 – 4.7) 0.527 
Hydrocephalus 0.7 (0.2 – 2.5) 0.545 
Skull Fracture 1.4 (0.4 – 4.9) 0.642 
Epilepsy 1.4 (0.4 – 4.9) 0.642 
* “Other” diagnoses included epidural hematoma, carotid artery occlusion, CNS 
vasculitis, hypoxic brain injury, carotid blowout, brain abscess, headache, meningitis, 
pancerebellar dysfunction, myasthenia gravis, venous sinus thrombosis, transverse 
myelitis, shunt malfunction, to encephalitis, gunshot wound to the head and Guillan-
Barre Syndrome. 
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 Medical History 
A variety of medical conditions were included in the univariate analysis and the results 
are summarized in Table 16. 
Table 16: Medical History and Association with VTE 
Characteristic OR (95% CI) P-value 
Atrial Fibrillation  1.2 (0.6 – 2.5) 0.682 
Prosthetic Valves 0.5 (0.1 – 4.5) 0.537 
Cardiomyopathy 8.3 (0.9 – 75.1) 0.060 
History of MI 6.3 (1.3 – 31.7) 0.025 
Hypertension 0.7 (0.4 – 1.1) 0.123 
Leg Fracture 0.2 (0.0 – 2.0) 0.188 
Prior VTE 4.8 (1.5 – 16.0) 0.010 
Malignancy 0.7 (0.4 – 1.4) 0.365 
Metastases 0.7 (0.2 – 2.0) 0.518 
Chronic Renal Insufficiency 1.4 (0.4 – 4.9) 0.642 
History of myocardial infarction (MI) and prior VTE were significantly associated 
with VTE.   
Several home medications were evaluated as potential risk factors and the results 
are summarized in Table 17.  None of the medications had were associated with VTE 
Table 17: Home Medications and VTE Association 
Medication OR (95% CI) P-value 
Aspirin 0.6 (0.3 – 1.3) 0.176 
Coumadin 1.9 (0.8 – 4.6) 0.153 
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Medication OR (95% CI) P-value 
Plavix 2.0 (0.5 – 8.4) 0.316 
Heparin 0.5 (0.1 – 4.5) 0.537 
Potential Risk Factors – In Hospital 
 
A number of in-hospital potential risk factors were investigated for association 
with VTE and the results are summarized in Table 18.   
Table 18: In-Hospital Interventions and Association with VTE 
Intervention OR (95% CI) P-value 
Central Venous Catheter 3.5 (2.2 – 5.7) <0.001 
Mechanical Ventilation 3.4 (2.0 – 5.8) <0.001 
Sedation 2.0 (1.3 – 3.1) 0.003 
Bed Rest 1.8 (0.5 – 5.5) 0.319 
Tracheotomy 1.5 (0.7 – 2.9) 0.272 
Paralytics 1.4 (0.5 – 3.4) 0.505 
Both mechanical ventilation and sedation were significantly associated with VTE.  
However, use of paralytics, tracheotomy and bed rest were not associated with VTE.  
Central-Venous Catheters 
 415 central-venous catheters, including PICC lines, were inserted.  Cases were 
more likely to have a catheter than controls.  Catheter placement appeared to be 
associated with both upper, (OR: 2.4 CI: 1.3 – 4.3, p=0.004) and lower (OR: 4.8 CI: 2.2 
– 10.5, p=0.000) DVTs.  See Table 19 for a summary of catheter site frequencies and 
association with VTE.  30 patients with VTE had a central-venous catheter on the same 
side as the clot prior to VTE diagnosis.  
 34 
  
. 
Table 19: Frequencies of Catheter Sites – Population as a Whole, and Association 
with VTE 
 
Catheter site Frequency 
Percentage of 
Total Catheters 
OR (95% CI) P-value 
Any Catheter 417 100.0% 3.5 (2.2 – 5.7) <0.001 
Femoral 29 7.0% 9.557 (2.7 – 34.2) 0.001 
Internal Jugular 26 6.3% 2.3 (1.0 – 5.6) 0.063 
PICC 102 24.6% 1.9 (1.1 – 3.2) 0.023 
Subclavian 257 61.9% 1.7 (1.1 – 2.6) 0.019 
 
Subclavian catheters (OR: 1.2, CI: 0.7 – 2.0, p=0.525) and PICC lines (OR: 1.5, CI: 0.8 – 
2.8, p=0.258) were not significantly associated with UEDVT.  However IJ catheters (OR: 
3.1, CI: 1.2 – 7.8, p=0.017) were significantly associated with UEDVT.  Femoral 
central-venous catheters were strongly associated with LEDVT (OR: 11.9, CI: 4.1 – 
34.4, p=0.000).  
Univariate Analysis: Summary of Positive Results: 
We identified 12 variables associated with VTE. They are summarized in Table 
20, below.  
Table 20: Factors associated with VTE on Univariate Analysis  
Variable 
Odds Ratio (95% 
Confidence Interval) 
P-value 
History of MI 6.3 (1.3 – 31.7) 0.025 
Prior VTE  4.8 (1.5 – 16.0) 0.010 
AVM 4.8 (1.5 – 16.0) 0.010 
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Central Venous Catheter 3.5 (2.2 – 5.7) <0.001 
Mechanical ventilation 3.4 (2.0 – 5.8) <0.001 
Intracerebral hemorrhage 2.3 (1.3 – 3.9) 0.004 
Plegia/paresis 2.2 (1.4 – 3.6) 0.001 
Sedation 2.0 (1.3 – 3.1) 0.003 
Height (cm) 1.03 per cm (1.01 – 1.05) 0.010 
Weight (kg) 1.02 per kg (1.01 – 1.03) 0.002 
Sex  (Female) 0.6 (0.4 – 1.0) 0.034 
VTE prophylaxis 0.16 (0.03 – 0.80) 0.025 
Multivariable Analysis 
 
The univariate variables from Table 20 were entered into a multivariable logistic 
regression analysis are shown in Table 21.  Of note, individual catheter types were not 
included in multivariable analysis because they each significantly correlated with catheter 
use overall and we wished to investigate catheter placement itself as a risk factor.  
Similarly, number of prophylaxis techniques was not included in multivariable analysis 
because it significantly correlated with overall prophylaxis use and we chose to use the 
dichotomous variable because we were trying to control for presence of prophylaxis.  
After multivariable analysis, significant variables included: presence of a central-venous 
catheter (OR: 2.5, CI: 1.4 – 4.6, p=0.003), AVM (OR: 4.9, CI: 1.2 – 20.0, p=0.026), 
mechanical ventilation (OR: 2.1, CI: 1.1 – 4.2, p=0.036), and documented prior VTE 
(OR: 5.6, CI: 1.4 – 22.4 p=0.014).  VTE prophylaxis was significantly protective (OR: 
0.1, CI: 0.0 – 0.9, p=0.043). 
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Table 21: Factors Associated with VTE: Multivariable Analysis 
Factor OR (95% CI) P-value 
Documented Prior VTE 5.6 (1.4 – 22.4) 0.014 
MI 5.5 (1.0 – 31.6) 0.056 
AVM 4.9 (1.2 – 20.1) 0.026 
Central-venous Catheter 2.5 (1.4 – 4.6) 0.003 
Mechanical Ventilation 2.1 (1.1 – 4.2) 0.036 
Plegia/Paresis 1.6 (0.9 – 2.8) 0.147 
Intracerebral Hemorrhage 1.6 (0.8 – 3.0) 0.190 
Sedation 1.2 (0.7 – 2.2) 0.474 
Female Gender 1.02 (0.50 – 2.08) 0.952 
Weight (kg) 1.01 per kg (1.00 – 1.02) 0.078 
Height (cm) 1.01 per cm (0.98 – 1.05) 0.438 
DVT Prophylaxis 0.8 (0.0 – 0.9) 0.043 
 
 To address the closely-related variables, a correlation matrix was developed, 
which showed significant correlation between mechanical ventilation, sedation, and ICH.   
Height and weight were also correlated, as were height and plegia.  However, all factors 
were included in the multivariable analysis because we had a reasonable belief that each 
could be independently associated with VTE.  P=0.639 on Hosmer Lemeshow indicating 
the model was a good fit.   
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DISCUSSION 
Incidence 
  Venous thromboembolism is a common cause of in-hospital morbidity and 
mortality.  Numerous patient subpopulations have been studied to date to investigate the 
incidence of, and risk factors for, VTE, in an attempt to tailor prophylaxis of VTE.  
However, despite the studies performed thus far, no study exists that specifically focuses 
on critically ill neurology and neurosurgery patients. This population’s unique diagnoses 
and high rates of surgery and immobility theoretically put it at higher risk for VTE.  
However, because VTE prophylaxis is not without cost and morbidity, it was important 
to investigate risk factors in this unique population, so that clinicians could identify those 
patients at highest risk for VTE and work to prevent this potentially fatal condition.  
Our findings demonstrated a NICU VTE rate of 9.5%, despite an overall 
thromboprophylaxis rate of 97.6%, a rate of prophylaxis higher than those of most 
previous studies investigating MICU and SICU populations.  The VTE rate of 9.5% is 
lower than that of the previously-studied MICU population (33%), and consistent with 
previously-studied neurorehabilitation (11%) and SICU populations (13%) (10, 15, 18).  
The lower rate of VTE may be due to the high thromboprophylaxis rate in our population.  
Interestingly, the rate of VTE was significantly higher than the 4% found in a previously-
studied neurosurgical population, suggesting patients requiring the ICU are, indeed, at 
higher risk of VTE compared to those with comparable diagnoses and surgeries on the 
neurosurgical floor (34).  Furthermore, of patients with VTE, over 38.4% had clinically 
apparent PE, a rate much higher than anticipated, although consistent with estimated rates 
of DVT propagation between 30% – 40% (13, 26).  Of course, we cannot account for 
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clinically silent PEs, as they are not screened for, so the true rate of PE may, in fact, be 
higher.  Furthermore, we cannot account for clinically silent DVTs which went 
undiagnosed, so the true percentage of VTE resulting in PE may, in fact be higher.  
In addition to a higher thromboprophylaxis rate, the rate of VTE may also be 
affected by possible ascertainment bias.  That is, only VTE for which a diagnostic test is 
performed have the potential to be discovered.  To explore this, we investigated the 
relationship between the number of scans performed per year and the number of VTE 
diagnosed, assuming that the true prevalence rate should not change year to year if the 
population characteristics and approach to prophylaxis did not change.  The number of 
scans per year and number of VTE diagnosed both varied over the years.   The number of 
ultrasounds was highest in 2004, the same year the number of VTE was highest.  This 
indicates that there may be ascertainment bias – the more scans performed, the more VTE 
diagnosed.  The yield was highest in 2001, the year with the fewest number of scans and 
VTE. This may indicate that more scans were performed for clinical suspicion in 2001, 
rather than for screening purposes, which would result in more VTE diagnosed and a 
lower yield.   
While the number of scans per year was significantly different, the number of 
scans was negatively correlated with VTE diagnosis.  That is, the number of VTE 
discovered did increase overall but the percent of positive scans decreased, indicating that 
ascertainment bias is less likely to be a major contributor.  Also, 110 controls received no 
ultrasounds at all, so it is certainly possible that there were VTEs in the control group that 
remained undiagnosed.  Furthermore, the number of scans per patient per week, did not 
differ significantly between cases and controls (p=0.061), though cases did tend to 
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receive more scans, on average.  Of course, cases, by definition, received at least one 
scan, so this may bias towards more scans among cases.  Finally, without a study in 
which screening ultrasounds are performed at regular intervals, the true rate of VTE will 
likely be underestimated.  
Upper-Extremity DVT 
One finding of particular interest was the rate of upper extremity DVT. There 
were 169 positive DUS for upper extremity clot out of 207 DUS performed on upper 
extremities – an 81.6% yield. This is likely due to the fact that upper extremity 
ultrasounds were primarily performed when there was clinical suspicion for DVT as 
opposed to routine screening. In comparison, there were 625 lower extremity DUS 
performed, and the yield was 19.4%.  This suggests that upper extremity DVT occurs 
slightly more frequently (4.3% of the total population) than the previously demonstrated 
1%-4% (42), and it may be prudent to include upper extremities in routine screening for 
DVT in NICU patients.   
One statistic further supporting the importance of UEDVT diagnosis was the high 
rate of PE among patients with UEDVTs. There was nearly an equal number of PEs 
associated with UEDVTs as LEDVTs (34.7% of PEs were potentially due to UEDVT or 
both UEDVT and LEDVT).   At least 11 out of 54 (20.4%) LEDVTs were associated 
with PE, and at least 9 out of 67 (13.4%) UEDVTs were associated with PE.  Thus, 
although the rate of clinically apparent PE was higher with LEDVT, the rate with 
UEDVT was not insignificant   
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Superficial Vein Thrombosis 
One other finding of particular interest was the high rate (3.2% of the total 
population) of cephalic vein thromboses - superficial vein thrombosis. While these 
thromboses are not considered DVTs, a high proportion did, in fact, extend into the deep 
venous system.  We found that 38.1% of cephalic thromboses ultrasounds were also 
positive for UEDVT, suggesting that cephalic clots are of clinical significance, if only 
because they are strongly associated with DVT.  In fact, 7 patients with “cephalic only” 
ultrasounds later proceeded to later develop PE.  However, it is possible that some of the 
ultrasounds positive for both UEDVT and cephalic clots began as an UEDVT which 
extended into the superficial system, rather than the reverse.  Therefore, further studies 
should be done to verify the rate of cephalic clots and their propagation into the deep 
venous system.  Given these findings, and the fact that SVT carries a 4.32-fold increased 
risk for VTE, additional studies may also be needed to investigate the efficacy of treating 
cephalic thromboses as DVTs (29).  Furthermore, additional studies investigating the 
rates of post-thrombotic syndrome in those patients with superficial vein thrombosis 
would be helpful to determine the extent of morbidity associated with cephalic 
thromboses.   
Thromboprophylaxis 
Another impressive finding was the high rate of thromboprophylaxis received by 
this patient population (over 97.6%).  The 9.5% rate of VTE, despite the high prevalence 
of thromboprophylaxis, may indicate the need for more effective thromboprophylaxis 
techniques, and for VTE screening even while patients are receiving thromboprophylaxis.  
Conversely, the fact that the rate of VTE is lower than that of MICU patients, as reported 
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in the literature, of which only 61% received prophylaxis, may be an example of effective 
prophylaxis at work (15). 
Also of interest is the use of multiple thromboprophylaxis techniques.  The 
majority (66.7%) of patients received two forms of thromboprophylaxis, most commonly 
a combination of SCDs and subcutaneous heparin bid.  Increasing number of 
thromboprophylaxis techniques was protective against VTE (OR: 0.6, CI: 0.4 – 0.9, 
p=0.013).    This may be an additional reason why the rate of VTE in the NICU was 
lower compared to other ICU populations.  Further studies may be needed to determine 
the efficacy and cost-effectiveness of using multiple prophylaxis techniques.  
Despite a 40-fold risk reduction with use of SCDs and heparin bid demonstrated 
in an earlier study (36), thromboprophylaxis did not appear to be as strongly associated 
with VTE reduction in the NICU.  However, due to the near universal use of prophylaxis, 
our study may not be able to accurately assess the association between SCDs, heparin bid 
and VTE.  
Finally, after multivariable analysis, VTE prophylaxis was shown to be 
significantly protective against VTE.  This verifies the value of VTE thromboprophylaxis 
in the NICU population.   
Risk Factors 
 Four potential risk factors for VTE in NICU patients were discovered after 
multivariable analysis: central venous catheter, AVM, mechanical ventilation and history 
of prior VTE.  In addition, history of MI and weight, while not statistically significant, 
were trended toward association with VTE.  These factors may be mechanistically related 
to VTE, that is, the direct cause, or may simply be markers for the true cause of VTE.  
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Central-venous catheter use (previously demonstrated OR: 5.55, CI: 1.57 – 19.58) (29), 
mechanical ventilation, documented prior VTE, weight and acute MI have all been shown 
to be VTE risk factors in other populations (12, 13, 29, 32, 58).  However, AVM has not 
been previously shown to be a risk factor for VTE, nor has a history of MI.  Given our 
findings, those patients undergoing mechanical ventilation, central-venous catheter 
insertion, suffering from AVM, or with a history of DVT, may have an identified risk for 
VTE compared to other NICU patients, though these risk factors need to be individually 
verified.  Studies investigating the efficacy of more aggressive thromboprophylaxis or 
screening for these patient populations are needed.   
AVM was found to increase the risk for VTE in the NICU population by 4.9-fold 
and may be useful as an admission screening tool.  To our knowledge, AVM is a 
previously undiscovered risk factor for VTE. The etiology of AVM as a risk factor is 
unknown as well.  However, one might speculate that the abnormal vasculature 
comprising the AVM may either predispose to a localized vasculitis or release of clotting 
factors.  Of note, there were 13 cases of AVM (3.5% of the NICU population), 3 of 
which had concurrent ICH.  Despite the relatively uncommon nature of AVMs, the large 
odds ratio for AVM as a VTE risk factor argues for the clinical importance of this risk 
factor.  Based on these findings, patients admitted to the NICU with AVM may be at 
higher risk for VTE.  Future studies are needed to investigate whether more aggressive 
screening and prophylaxis would be of clinical benefit for these patients.   
Central venous catheter placement has also been shown to be a risk factor for 
VTE in the NICU population and is a previously-demonstrated VTE risk factor in other 
populations.   In fact, among the general population, placement of a central venous 
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catheter has been shown to increase the odds of VTE by 5.55 (29).  Our study found that 
central venous catheter placement carries an odds ratio of 2.5, lower than that of previous 
studies.  The risk is likely lower because, in a population with a higher background risk 
of VTE, the relative additional increase in risk from central-venous catheter, while high, 
is lower compared to populations without any existing risk factors for VTE.  The finding 
that catheter placement is a risk factor for VTE in the NICU, is of great relevance 
because 41.1% of the NICU population received a central venous catheter, placing a large 
portion of this population at nearly three-times the risk of VTE.   
Mechanical ventilation is a known risk factor for VTE (11).  Our study 
demonstrates a 2.1-fold increase in VTE risk.  This is of particular interest in the NICU 
population due to the high rate of mechanical ventilation (65.8%).   Mechanical 
ventilation may be used as a “red flag” for VTE in the NICU and future studies are 
needed to investigate whether more aggressive screening and thromboprophylaxis would 
decrease the risk of VTE in patients undergoing mechanical ventilation.   
Prior VTE is a known risk factor for VTE.  While patients with known history of 
VTE would theoretically be well screened and appropriately prophylaxed, it was 
important to verify this as a risk factor for VTE in the NICU population.  There were only 
13 patients (3.5% of the population) with known history of VTE.  Therefore, while the 
frequency of patients with this condition is low, the utility as a screening factor is not, 
due to the high associated OR (5.6).  In fact, patients with prior VTE had the greatest 
increased risk of VTE after multivariable analysis.   
Acute myocardial infarction is a known risk factor for VTE and, in fact, 33% of 
patients not receiving thromboprophylaxis after acute MI developed VTE (59).  
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Interestingly, debate exists over whether common risk factors for cardiovascular disease, 
including hypertension and dyslipidemia, are also risk factors for VTE.  A 2002 study 
showed no association of cardiac risk factors with VTE, while a recent, 2008 study, did 
(60, 61).  However, history of myocardial infarction has not previously been 
demonstrated to be a risk factor for VTE.  History of MI was shown to be trending 
toward association with VTE, in the NICU population, though not statistically significant 
(p=0.056).  History of MI, though rare (2.1%) is a useful screening tool, since this past 
medical history should be known upon admission to the NICU.   
Weight, another previously-known VTE risk factor, was also shown to be 
trending towards association with VTE, though not statistically significant (p=0.078).  
The OR of 1.01 per kg indicates that the increased risk of VTE is incrementally small per 
kg.  Further studies are needed to more specifically determine if there is a weight at 
which the risk of VTE rises to the level of requiring more aggressive screening and 
prophylaxis.   
Morbidity/Mortality 
VTE was significantly associated with longer median NICU stays (18.5 days 
[IQR: 10 – 30] vs. 6 days [IQR: 4 – 11], p=0.004) and hospital stays (31 days [IQR: 16.5 
– 46] vs. 13 days [IQR: 8 – 19], p<0.001.)  Interestingly, while there was a higher rate of 
overall mortality associated with VTE (15.1% of cases vs. 8.7% of controls, p=0.060), 
and VTE was correlated with a 1.9-fold increase in death, there was only one death 
attributable to PE.  This low rate of death attributable to PE may have been due to 
difficulty determining cause of death from the charts and the low rate of autopsies 
performed.  However, patients with VTE may have been sicker than controls, and 
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therefore, VTE may be a marker for patients at increased risk for death.   The fact that 
VTE was not significantly associated with death on multivariable analysis indicates that 
VTE may simply be a marker for increased risk of death, rather than an actual risk factor.  
The rates of heparin-induced thrombocytopenia (HIT) and bleeding were both 
very low, and, while there were two cases of HIT among the cases, there were no 
episodes of serious bleeding among cases. Presumably the rates of bleeding were so low 
because patients at risk for hemorrhage had IVC filters placed rather than being 
anticoagulated.  However, this hypothesis would require further investigation.  None of 
the patients with either HIT or serious bleeding died during their hospitalization.   
 
STRENGTHS OF THE STUDY 
 This study has several important strengths. First, it is relatively large – 
investigating a NICU population of 1,318 patients over 5 years.  A total of 375 patients 
were investigated in detail. The remarkably detailed data collected allowed for a more 
complete analysis of the NICU population as a whole and of potential risk factors.  Data 
collection was obtained directly from the chart and did not rely on ICD-9 codes, 
increasing the reliability of data collection and, in particular, case identification.  
Furthermore, the fact that each VTE diagnosis was confirmed and all 1,318 potential 
patients had the veracity of their VTE status verified, improves the validity of our 
incidence calculations.  Finally, this is the first study of the NICU population, which has 
a high rate of thromboprophylaxis, and several useful risk factors were identified.  These 
risk factors, once validated, may be of great clinical utility.  
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LIMITATIONS 
There are several limitations to our study. First, the population studied was 
limited to NICU patients admitted for longer than three days.  Therefore, conclusions 
drawn from this study are limited to this specific patient population and we cannot draw 
any conclusions about NICU patients admitted for less than 3 days.  Additionally, there 
were only 125 cases of VTE in this population, thus leading to wide confidence intervals 
and limiting our statistical power to fully investigate potential risk factors.   However, our 
total number of cases was much greater than that of one similar previous study (15) and 
similar to others (31, 18). 
Another potential limitation of this study is that cases and controls were matched 
based on whether they received surgery of any kind during their hospitalization.  
However, they were not matched based on length or type of surgery.  In fact, upon 
review, there are 13 cases that received surgery after the diagnosis of VTE and therefore 
may not be true matches.  However, upon further analysis of the dataset with those 13 
cases and their respective controls removed, the statistically significant factors on 
univariate analysis were unchanged other than the exclusion of sex.  After multivariable 
analysis, the significant factors remained unchanged, though history of MI was also 
significant and the OR for each variable was affected. This indicates that those 13 
mismatched cases did not affect the ultimate conclusions regarding our above stated 
potential risk factors.  However, further studies are needed to verify the rates of surgery 
and the conclusions of this study with surgery correctly controlled for, particularly the 
ORs.    
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One potential limitation to the finding of only one death attributable to PE is that 
official cause of death was difficult to determine in many cases.  Patients generally 
suffered from multiple serious medical conditions, so an exact cause of death could not 
be determined in many cases. In such cases, those deaths were coded as not attributable 
to PE.  Therefore, the true number of deaths attributable to PE may be higher, particularly 
given the higher rate of overall mortality among cases vs. controls.   
Another limitation is the inability to be completely certain that all VTE were 
diagnosed.  There is always a possibility that clinically silent VTEs occurred, which was 
not detected on screening.  However, a large number of scans were performed, making 
the possibility that VTEs were missed due to a paucity of scans, less likely.  However, 
only a study which screens for VTE at regular intervals could determine the precise 
incidence of VTE in this population.  Additionally, it is possible that documented “prior 
VTE” in certain patients was still present upon NICU admission and not a new clot 
developed while in the NICU.  Also, due to inconsistencies with recording hemorrhagic 
strokes, we were unable to study this known risk-factor, as a potential risk factor in the 
NICU population (34). Nasogastric tube and urethral catheter were nearly universal in 
their use in the NICU and therefore unable to be studied as potential risk factors in the 
NICU (35).   
Limitations intrinsic to all retrospective studies must be acknowledged as well.  
Many of the risk factors studied were not hypothesized beforehand.  Rather, we used 
univariate logistic regression to identify potential associations.  Therefore, the risk factors 
determined by this study require validation.  Furthermore, we did not perform a statistical 
adjustment for multiple comparisons, again, indicating the need for future validation.  
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Also, we cannot account for the potential for residual confounding by factors not 
included in our multivariable analysis.  Finally, intrinsic to all case-control studies, we 
cannot test for the factors which were controlled for, mainly year and presence of 
surgery.  While preliminary analysis shows different rates of VTE across the 5 years, 
future studies are needed to further investigate this trend, as well as surgical trends.   
An additional limitation is that ICH, mechanical ventilation and sedation were all 
correlated.  Each of those factors was included in the multivariable analysis despite this 
correlation because they still had potential to be independently associated with VTE.  
Therefore, future studies are needed to validate our findings after controlling for potential 
interactions among variables.   
 Finally, limitations due to the population size must be addressed. Due the 
relatively small patient number, many of the confidence intervals were quite wide and 
ORs are unstable.  That is, with the addition or loss of even a few patients, the ORs may 
change dramatically.  However, those factors with more narrow confidence intervals are 
more likely to be truly significant and not subject to instability based on population size.  
Therefore, while we can be confident in our conclusions regarding association with VTE, 
a larger study repeating this investigation is needed to give more precise estimates of OR.   
Also, due to the size of the study, we were unable to include previously-demonstrated 
risk factors that had p>0.05 into our multivariable analysis.  Only those factors with 
p<0.05 on univariate analysis were included in multivariable analysis. This study does 
not disprove the role of those known variables as risk factors in the NICU population.  
Rather, they require further investigation as potential risk factors in the NICU.  
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IMPLICATIONS AND FUTURE DIRECTIONS 
This study of VTE in the NICU population contributes to our understanding of 
which patients are at particular risk for VTE, which may prove helpful to clinicians 
caring for this population.  Future investigation is needed to confirm the findings in this 
study.  Additional studies into whether more aggressive surveillance and prophylaxis, in 
fact, decrease rates of VTE, are needed.  Finally, further investigation into the morbidity 
and mortality associated with cephalic clots, is needed.   
CONCLUSION 
In conclusion, we found a VTE rate of 9.5% in the NICU population, despite a 
high rate of thromboprophylaxis.  There was a trend towards increased mortality in 
patients with VTE and a significant increase in length of hospital and NICU stay.  The 
study also uncovered a high rate of upper-extremity DVTs and SVTs, many of which 
appeared to propagate into the deep venous system.  There was also a large number of 
PEs that was potentially due to upper-extremity DVTs.  These findings, taken as a whole, 
argue for further investigation of more aggressive upper-extremity DVT screening and 
thromboprophylaxis.  Further studies are also needed to investigate the potential 
morbidity, cost and benefits associated with treating cephalic thromboses as DVTs.   
Risk factors for VTE in this patient population include central-venous catheter 
use, mechanical ventilation, history of VTE and diagnosis with AVM.  History of MI and 
increasing weight were trending toward association with VTE.  Future studies will need 
to be done to determine if patients with these factors would benefit from more intensive 
surveillance and prophylaxis. 
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TABLES and FIGURES 
Table 1 – Previously Determined Risk Factors for VTE (13, 29, 32) 
Surgery 
Trauma (Major or lower extremity) 
Immobility 
Paresis 
Malignancy 
Cancer therapy (chemotherapy, hormonal, radiotherapy) 
Previous VTE 
Increasing Age 
Pregnancy and the postpartum period 
Heart or Respiratory Failure 
Inflammatory Bowel Disease  
Smoking 
Estrogen and selective estrogen receptor modulators 
Nephrotic Syndrome 
Obesity 
Myeloproliferative Disorders 
Central Venous Catheterization 
Inherited or acquired thrombophilia – Factor V Leiden, Protein C or S deficiency, 
Antithrombin deficiency, prothrombin gene mutation 
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Acute medical illness 
Spinal cord injury 
Varicose veins 
 
 
Table 2: Summary of Prior Studies Demonstrating Thromboprophylaxis Efficacy 
 
Table from Reference 13, p. 137S 
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 Table 3: Summary of Rationale for Thromboprophylaxis in Hospitalized 
Patients
 
Table from Reference 13 p.339S 
 
Table 4: Meta-analysis of DVT Prevalence in Critical Care Populations Previously 
Studied, Not Receiving Thromboprophylaxis 
 
Table from Reference 13 p.373S 
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Table 5: DVT Prevalence Among Previously Studied Populations 
 
Table from Reference 13 p.340S 
 
FIGURE  1 
Data Collection Form: NICU study of DVT/PE4 
Demographics: 
• MRN: __________ 
• Date of hospital admission:  ________ 
• Date of hospital discharge: ________ 
• Date of NICU admission:  _________ 
• Date of NICU discharge:  __________ 
• Date of birth:  ___________ 
• Sex (circle):  M / F 
• Race (circle):  White   Black    Hispanic   Asian   Other 
• Height (cm): _____ 
                                                 
4
 See Appendix 1 for sources used for data collection, as well as, definitions and rules for each data piece. 
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• Weight (kg): _____  
Status Upon NICU Admission 
 
• Primary Diagnosis upon admission to NICU: (circle) 
o Stroke:  Thrombotic  Hemorrhagic 
o Brain Tumor 
o Spinal Cord Injury 
o Hemorrhage: Subdural Subarachnoid      Intracranial 
o Hydrocephalus 
o Cerebral aneurysm 
o Pharmacologically resistant epilepsy 
o Other (specify): _____________________ 
• Neuro exam results upon admission to NICU: 
o GCS: 
o Plegia/paresis (circle):    Paraplegic        Quadraplegic  
o Limb side (circle):   Left    Right 
 
Medical History:  
(As documented upon NICU admission.  Circle any applicable conditions) 
 
• Cardiac:  Atrial fib.    Prosthetic valve(s)    Myocardial infarct.    Cardiomyopathy 
• Nephrotic Syndrome   
• Leg fracture (in a cast/on crutches/ immobilized) 
• Smoking status:  Current     Former     Never 
• Alcohol intake:  
o No EtOH  Non-abusing level  
o EtOH (social or one drink per day)  
o   Abusing/excessive level EtOH (larger quantity recorded or “alcoholic”) 
• Documented prior DVT or PE: 
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  DVT  Date of DVT diagnosis:  ________________ 
PE  Date of PE diagnosis:  ________________ 
 Actively being treated at time of NICU admission?   YES      NO 
 Filter:  YES  NO 
• Malignancy (w/in 12 mos, other than non-melanoma skin cancer:   YES    NO  
Metastatic:       YES NO 
• Hypercoagulability state:   YES    NO 
(Includes: Factor V Leiden, Antiphospholipid Antibody Syndrome, Factor S deficiency, Factor C 
deficiency, Heparin-induced thrombocytopenia syndrome, Mutation in methyltetrahydrofolate 
gene, Prothrombin mutation, Hyperhomocystenemia, Antithrombin III deficiency) 
 
• Pregnant (currently):    YES     NO 
Current Medications/Drugs upon NICU admission (circle): 
Estrogen (HRT)    Birth Control     
Coumadin      Heparin Plavix       Aspirin 
Other related drugs (specify): _______________ 
Procedures/Conditions During Nicu Stay  (including 3 days prior) 
Post-NICU admission meds (circle): 
o Estrogen (HRT)       Birth control  
o SQ heparin  5000 bid           SQ heparin 5000 tid 
o Lovenox 30 mg/d (LMWH)            Clopidogrel/Plavix 
o Aspirin 324 mg/d                  
o Mechanical device    
o Other related anticoagulants___________ 
• Bed Rest – assumed unless documented as ambulatory:  YES  NO 
• Mechanical Ventilation (within 3 days prior to NICU admission or any time during NICU stay):   
  
 
o YES  NO 
 
o date of first ventilation day in NICU:__________ 
 
defined as a day where the patient is ventilated for more than 3 hours for reasons 
other than surgery 
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(only the first time if there were periods without ventilation) 
o date of last ventilation day in NICU:_________ 
 
(the very last time if there were periods without ventilation) 
• Intubation (if length of time between multiple intubations is <48 hours, count as one intubation 
episode) 
 
o date of insertion ____________________________ 
o date of removal _____________________________ 
• Sedation – continuous infusions only (record dates of start/finish) 
 
o Fentanyl: start:______ finish:_______                     
o Morphine:  start:______ finish:_______                     
o lorazepam (Ativan):  start:______ finish:_______                     
o midazolam (Versed) start:______ finish:_______                     
o propofol (Diprivan)   start:______ finish:_______    
o Other:_____________   start:______ finish:_______    
• Paralytics: (record dates of start/finish):  
 
o YES   NO   
o Start date:______  
o Finish date :_______                     
• Catheters:  
 
o groin catheter #: ____________ LEFT  RIGHT 
o dates:  insertion ________  removal ________  
o subclavian  #: ____________ LEFT  RIGHT 
o dates: insertion _______ removal _________ 
o IJ line #: ____________  LEFT  RIGHT 
o Dates: insertion _______   removal ___________ 
• Tracheostomy:   YES  NO 
o Date:_________ 
 
• Blood transfusion during stay:  YES   NO 
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• Urethral catheter:  YES  NO 
 
o Dates: insertion ________ removal_______________ 
• Feeding tube:      YES  NO 
 
o Dates:  insertion________________removal ___________ 
Surgery 
• Surgery:  Y  /  N 
 
o Date: ________ 
o Length to the minute:______ 
o Type (circle): 
Tumor removal       Evacuation of blood         Shunt insertion  
Vascular surgery (aneurysm/AVMs etc) Other:______________ 
o Craniotomy:   YES   NO 
• Prophylaxis: type/dosage used intraoperatively (circle): 
 
o SQ heparin  5000 bid 
o SQ heparin 5000 tid 
o Lovenox 30 mg/d (LMWH) 
o Clopidogrel/Plavix 
o Aspirin 324 mg/d 
o Mechanical Device 
o Other  
DVT Diagnosis  
• Date of DVT diagnosis:______________ 
• Date of PE diagnosis (if applicable):________________ 
 (including within two days of discharge from NICU)  
• Test(s) used to diagnose: (circle and fill in date of every test): 
 
o DUS            POS  NEG 
o  Date_________________ 
 
o V/Q       POS  NEG 
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o  Date_________________ 
 
o Pulmonary angiography      POS  NEG 
o Date_________________ 
 
o Venography     POS  NEG 
o Date_________________ 
o CT angiography     POS  NEG 
o Date_________________ 
o Other    Date_________________ 
• Why the test was done (circle):  
 
o routine (e.g., biweekly, standing order test) 
o clinical suspicion (e.g., special doctor’s order due to presence of S/S 
• Ambulatory status upon diagnosis (assumed immobile unless documented as ambulatory) 
(circle):  
  
  Ambulatory        NOT  ambulatory 
• Prophylaxis in use prior to diagnosis (type, dose, frequency, route): 
 
o SQ heparin  5000 bid 
o SQ heparin 5000 tid 
o Lovenox 30 mg/d (LMWH) 
o Clopidogrel/Plavix 
o Aspirin 324 mg/d 
o Mechanical  
• Mechanical prophylaxis prior to diagnosis (include dates initiated/discontinued if more than 3 
hours per day): 
 
o Intermittent external pneumatic calf compression (IPC)/Venodyne boots dates: start 
________   finish   ________________ 
o Graduated compression stockings/TED stockings 
dates: start ________   finish   ________________ 
o Electrical stimulation of calf muscles 
dates: start ________   finish   ________________ 
o Rotating tables  
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dates: start ________   finish   ________________ 
• Location of DVT if documented (circle): 
o LEFT   RIGHT 
 
  proximal lower limb                   distal lower limb  
proximal upper limb  distal upper limb 
• Presence of PE at time of DVT diagnosis:  YES  NO 
 
(based on concurrent diagnosis) 
 
• Presence of and type of associated symptoms at time of diagnosis (circle if applicable): 
 
o palpable cords:  Left  Right  
o swelling  Left  Right 
o redness   Left  Right 
o warmth   Left  Right  
o pain    Left  Right 
DVT TREATMENT UPON DIAGNOSIS (CIRCLE ALL APPLICABLE): 
• IVC filter:  Date of insertion:  _______________ 
 
• Pharmacological: circle dose/freq/route 
 
o Date initiated: _____________ 
o IV unfractionated heparin 
o SQ LMWH  
o Coumadin 
o Other 
• Radiological intervention  
 
o Date_______________ 
o Type___________________ 
COMPLICATIONS/NEGATIVE OUTCOMES: circle any applicable  
• Pulmonary embolism: 
 
o date of diagnosis___________________________________________ 
o test used to diagnose_________________________________________ 
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o treatment_________________________________________________ 
• Bleeding  (defined as hemorrhage requiring a blood transfusion or intracranial hemorrhage as 
demonstrated by change in neuro exam and supported by CT scan) 
 
o date diagnosed:______________ 
o transfusion required:     YES      NO 
• Venous ulceration  
 
o Date diagnosed:___________ 
o Limb:         L     R 
• Death  
 
o Date of death (must be within 3 days of d/c):________________ 
 
o Related to the PE?:         YES       NO 
 
(Record all deaths in the time frame so can report percentage of deaths attributed to DVT/PE) 
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APPENDIX 1 
Specific information gathered and rules for each data piece (source of information, definition of 
positive result) are contained below: 
Demographics: 
• MRN:  Excel file. 
• DOB:  SCM Patient info section or from paper chart. 
• Hospital admission/discharge dates:  Excel file. 
• NICU dates: Dates of first and last acute care flow sheets, provided stay was three days or longer. 
(If there was a break between 3+ day stays, entered the very first day and the very last day.)  If 
there was any indication in progress notes or discharge summary that part of hospital stay was in a 
non-neuro ICU, the progress notes were thoroughly reviewed so that the accurate NICU-specific 
flow sheets were reviewed.  
• Race and Gender:  SCM 
• Height (inches) /Weight (kilograms):  Obtained from nursing admission assessments, paper chart 
or CCSS, anesthesia pre-op or intra-operative flow sheets, or from nutrition initial assessment. 
Occasionally the weight was obtained from the daily flow sheets.  
Status Upon NICU Admission: 
• Diagnosis: Primarily obtained from discharge summary. If a secondary diagnosis was listed, (e.g., 
subarachnoid hemorrhage due to cerebral aneurysm), both were recorded.  Occasionally, diagnosis 
was obtained from the patient info section on SCM or CCSS. 
• GCS: First GCS listed on first acute care flow sheet. If the patient was intubated or had a C for 
eyes closed, only the number was recorded. For example, if the GCS was 7I on the flow sheet, a 
GCS of 7 was entered. However, if the GCS was recorded as less than 3, it was recorded as 3. 
•  Plegia/Paresis: Obtained from discharge summary and was the status upon admission to the 
NICU.  If the patient was recorded as moving all fours, or 5/5 strength, or good strength on the 
progress notes or discharge summary, then it was assumed no paresis/plegia was present. Also, if 
it was recorded in the discharge summary that the patient did, in fact, have a hemiparesis, even if 
not initially recognized, that was recorded as a hemiparesis.  
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Medical History: 
• Medical History:  Obtained from Discharge summary, progress notes, occasionally CCSS. 
Specific medical history data recorded included: 
o Cardiac:  recorded hypertension, presence of prosthetic valves, congestive heart failure 
(CHF), cardiomyopathy, hypercholesterolemia/lipidemia, Diabetes Mellitus (DM), 
myocardial infarction (MI), and coronary artery disease (CAD). There was also a place 
for “cardiac other.” 
o Renal:  nephrotic syndrome or chronic renal insufficiency (CRI). 
o Fracture: leg fracture, or arm fracture. 
o Smoking/Alcohol status: Obtained from admission nursing assessment in CCSS or chart, 
from anesthesia notes, or progress notes.  Smoking status was recorded as current, 
former, or never.  Alcohol status was recorded as either none, non-abusing (1-2 
drinks/day), or abusing/excessive  (>2 drinks/day).  Abusing/excessive was also recorded 
for those patients listed in the chart as a known EtOH user, alcoholic, abuser or drinker.   
o Prior DVT/PE, including date and treatment prior to admission:  Obtained from progress 
notes, discharge summary, and occasionally, from the diagnostic imaging on SCM. 
o Malignancy: Non-melanoma skin cancer was not included. Only malignancies within the 
past 12 months were considered positive. Whether malignancy was metastatic was also 
included. Primary brain tumors generally not considered metastatic, e.g., GBM or 
oligodendroglioma.  
o Hypercoagulable state (hereditary): If documented, or discovered during hospital stay, the 
disorders were listed on the form.  
o Pregnant – If documented anywhere in chart.  
• Admission Medications: Documented home medications were obtained from progress notes, and 
included anything relating to sedation or anticoagulation initiated in the emergency department. In 
addition to those listed, heparin, Lovenox and Vioxx/Celebrex were also recorded. 
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Procedures/Conditions During NICU Stay: 
• Post-NICU Medications (including mechanical prophylaxis): Any relevant medications were 
recorded.  Information obtained from 7MED medication administration documents, order sheets or 
patient records for drugs.  Recorded relevant drugs administered at any time during NICU stay.  
Mechanical device information was obtained from acute care flow sheets.  
• Bed Rest:  Assumed, unless documented as out of bed (OOB) within the first 3 days of stay. 
• Mechanical Ventilation:  Patient was considered to receive mechanical ventilation if on a 
ventilator, CPAP, or BiPAP. For the specific dates of mechanical ventilation, a day was defined as 
a day where the patient is ventilated for more than 3 hours for reasons other than surgery.  If there 
were multiple ventilation periods, the first date is the first date recorded as having mechanical 
ventilation, and the last date is the last date recorded from acute care flow sheets, despite periods 
without ventilation.  
• Intubation:  The first date and last date were obtained from flow sheets. Again, intubation defined 
as being intubated longer than three hours, consecutively, for reasons other than surgery. Again, if 
there were periods in between without intubation, only the first and last dates were recorded.  
• Sedation:  We had originally intended to record first date and last dates of sedation, but later 
determined the presence or absence of sedation for longer than six hours was a more relevant 
finding.  Continuous infusions were only as listed on acute care flow sheets, and were the only 
form of sedation considered positive.  That is, intermittent injections or intermittent oral doses of 
benzodiazepines were not considered positive.  
• Paralytics: For paralytics, start and end dates were recorded for any period of paralysis longer than 
six hours. If multiple times, then the very first and last were recorded. This data was obtained from 
acute care flow sheets (continuous infusions only).  
• Catheters: Use of internal jugular (IJ), subclavian, PICC, and femoral lines were considered 
positive.  Dates inserted and removed based on acute care flow sheets were recorded, as was body 
side. Occasionally, if ultrasound record of a catheter was present on SCM, that was used as well. 
• Tracheostomy during hospitalization: This was obtained from the operative note on SCM, or in 
chart, from discharge summary, or from anesthesia assessments.  
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• Blood Transfusion:  Based on transfusion record in chart. 
• Urethral Catheter and Feeding Tubes: Initially recorded for cases, but not recorded for controls, as 
we did not deem them as potential risk factors to investigate at this time, and results would be 
confounded by the increased immobility of patients with these devices. 
Surgery: 
• Surgery: Details were based on operative report. Start and stop time from circulator nurse record, 
secondarily from the anesthesia intraoperative record.  The type of surgery performed was 
categorized as evacuation of blood, tumor removal/biopsy, spinal surgery (e.g., fusions),. or 
vascular (e.g., aneurysm clipping/coiling). We also recorded craniotomy or burr hole technique if 
recorded on operative report or intraoperative records.  
• Intraoperative Prophylaxis:  Recording was based on circulator nurse flow sheet. If heparin 2000 
units or more was documented as being administered, then this information was recorded.  
DVT Information: 
• DVT Information: Date of PE or DVT diagnosis based on first positive diagnostic imaging result. 
• DVT Imaging : Information gathered from SCM.  As described above, all DUS, V/Q, CTA, and 
relevant venography/angiography results were documented for the entire hospital stay, both 
positive and negative, including date, limbs imaged if relevant, as well as V/Q results as low, 
intermediate, or high probability.   
• Signs and Symptoms:  Any signs or symptoms leading to the imaging were obtained from the 
imaging report or from the discharge summary or progress notes.  If there were any 
signs/symptoms present at the time of the imaging modality, the imaging was considered to have 
been conducted based on clinical suspicion.  If only “prolonged ICU stay” or “bed rest” or 
“immobility” were listed on the imaging report, the screening test was considered routine.   
• If there was a PE at the time of DVT diagnosis, or vice versa, then that information was gathered 
from the SCM diagnostic imaging.  Positive results were defined as above, and were recorded in 
detail – occlusive vs. nonocclusive, limb side, and all veins involved. Ambulatory status on 
diagnosis was based on the acute care flow sheet and occasionally progress notes.  Patients were 
considered not ambulatory unless documented as being “ad lib” or “OOB”.   
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• Prophylaxis used prior to diagnosis was based on flow sheets (for mechanical devices) and 7MED 
summaries.   
• Mechanical prophylaxis start and end dates were recorded for cases only, in an attempt to 
document use prior to DVT.  However, only the use or non-use of mechanical prophylaxis during 
the NICU stay was documented for controls. 
DVT Treatment Upon Diagnosis: 
• Treatment information for PE/DVT was based on several sources.  IVC filter placement date was 
primarily from SCM, although occasionally from the discharge summary.  Pharmacologic 
information was obtained from flow sheets for heparin drips and from 7MED summaries for all 
other pharmacologic interventions.  
Complications/Negative Outcomes: 
• Pulmonary embolism details were obtained from the sources above, primarily SCM for date, and 
method used to diagnose.  Treatment was from SCM (IVC filter), discharge summary, and 7MED 
summary.   
• Bleeding:  Defined as hemorrhage requiring a blood transfusion, or intracranial hemorrhage as 
demonstrated by change in neuro exam and supported by CT scan.  Based on mention in the 
discharge summary and supported by progress notes or radiographic confirmation.   
• Venous Ulceration: Based on mention in discharge summary, and corroborated by progress notes 
noting date and  limb side. 
• Heparin-Induced Thrombocytopenia (HIT):  Recorded if developed or not, based on discharge 
summary. 
• Date of Death: Based on SCM patient info section and corroborated by acute care flow sheets.  All 
deaths were recorded, but were only documented as due to PE if autopsy report indicates, or if 
death appears to be due to hypoxic event in/around time known PE was diagnosed, and no other 
obvious cause of death is apparent (e.g., patient not known to be rebleeding or herniating).   
 
 
